Step Pharma, Sas
Clinical trials sponsored by Step Pharma, Sas, explained in plain language.
-
New drug STP938 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called STP938 in adults with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and check how the body processes the drug. A special focus is on ovarian cancers missing a certain gene. About 7…
Phase: PHASE1 • Sponsor: Step Pharma, SAS • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for patients with Hard-to-Treat blood cancer?
Disease control Recruiting nowThis early-stage trial tests a new drug called STP938 in 20 adults with high risk essential thrombocythaemia (ET), a rare blood disorder causing too many platelets. Participants have not responded well to or cannot tolerate the standard treatment hydroxycarbamide. The study aims …
Phase: PHASE1 • Sponsor: Step Pharma, SAS • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New hope for tough lymphomas: first human trial of STP938 begins
Disease control Recruiting nowThis study tests a new drug called STP938 in adults with B-cell or T-cell lymphoma that has returned or not responded to at least two prior treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 180 participants will receive STP938 alone, with th…
Phase: PHASE1, PHASE2 • Sponsor: Step Pharma, SAS • Aim: Disease control
Last updated May 04, 2026 16:22 UTC